Skip Nav Destination
Issues
1 May 2023
EISSN 2573-7732
ON THE HORIZON
Dual TCR-Expressing T Cells in Cancer: How Single-Cell Technologies Enable New Investigation
Immunohorizons (2023) 7 (5): 299–306.
INFECTIOUS DISEASE
Evidence for Aerosol Transfer of SARS-CoV-2–Specific Humoral Immunity
Ross M. Kedl; Elena W. Y. Hsieh; Thomas E. Morrison; Gabriela Samayoa-Reyes; Siobhan Flaherty; Conner L. Jackson; Rosemary Rochford
Immunohorizons (2023) 7 (5): 307–309.
B Cell Chronic Lymphocytic Leukemia Development in Mice with Chronic Lung Exposure to Coccidioides Fungal Arthroconidia
Immunohorizons (2023) 7 (5): 333–352.
CD8+ Regulatory T Cells Induced by Lipopolysaccharide Improve Mouse Endotoxin Shock
Nanaka Morita; Masato Hoshi; Hiroyuki Tezuka; Tatsuya Ando; Sayaka Yoshida; Fumiaki Sato; Hiroyuki Yokoi; Hiroyasu Ito; Kuniaki Saito
Immunohorizons (2023) 7 (5): 353–363.
CLINICAL AND TRANSLATIONAL IMMUNOLOGY
The Plasma Cell Infiltrate Populating the Muscle Tissue of Patients with Inclusion Body Myositis Features Distinct B Cell Receptor Repertoire Properties
Roy Jiang; Bhaskar Roy; Qian Wu; Subhasis Mohanty; Richard J. Nowak; Albert C. Shaw; Steven H. Kleinstein; Kevin C. O’Connor
Immunohorizons (2023) 7 (5): 310–322.
SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties
Michael C. Warren; Stephan Matissek; Matthew Rausch; Marisella Panduro; Richard J. Hall; Austin Dulak; David Brennan; Sonia Das Yekkirala; Secil Koseoglu; Ricard Masia; Yu Yang; Navamallika Reddy; Robert Prenovitz; Jamie Strand; Tauqueer Zaidi; Erik Devereaux; Célia Jacoberger Foissac; John Stagg; Benjamin H. Lee; Pamela Holland; Vito J. Palombella; Andrew C. Lake
Immunohorizons (2023) 7 (5): 366–379.
EDITORIAL
Negative Data, Oh No What Should I Do? How Publication of Negative Data Removes Roadblocks to Productive Research from the Perspective of Scientists Who Perform the Experiments
Angela K. Beltrame; Johnathon J. Caldon; Cody J. Gurski; Zivar Hajiyeva; Nathan J. Meinhardt; Kelli C. Sommers; Savannah D. Neu; Bonnie N. Dittel
Immunohorizons (2023) 7 (5): 380–383.
-
Cover Image
Cover Image
![issue cover]()
On the cover: Immunohistochemistry for human IgG4 demonstrates penetration of the anti-CD39 Ab SRF617 into the tumor microenvironment in a mouse orthotopic pancreatic cancer model. Strong staining is seen in the stromal compartment in viable areas of SRF617-treated tumors (pictured). Isotype-treated tumors show no staining in viable areas. Warren, M. C., S. Matissek, M. Rausch, M. Panduro, R. J. Hall, A. Dulak, D. Brennan, S. D. Yekkirala, S. Koseoglu, R. Masia, Y. Yang, N. Reddy, R. Prenovitz, J. Strand, T. Zaidi, E. Devereaux, C. J. Foissac, J. Stagg, B. H. Lee, P. Holland, V. J. Palombella, and A. C. Lake. 2023. SRF617 is a potent inhibitor of CD39 with immunomodulatory and antitumor properties. ImmunoHorizons 7: 366–379.
- PDF Icon PDF LinkEditorial Board
